All sponsors

CanSino Biologics Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS2
Open CanSino Biologics Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
MCV4
NCT06226714
P3Active, not recruitingMeningococcal Meningitis8402024-09-26
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)
NCT05951725
P3Active, not recruitingDiphtheria, Tetanus and Acellular Pertussis25202025-04-01
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)
NCT06857370
P3Active, not recruitingDiphtheria, Tetanus and Acellular Pertussis7802026-01
Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
NCT06577298
P1/2Active, not recruitingPoliomyelitis4802026-10
24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)
NCT07600983
P1/2RecruitingStreptococcus Pneumoniae Infection8542026-11-24
PCV13i
NCT07017777
P3Active, not recruitingPneumococcal Infections; Streptococcal Infections6002027-02-15